ArticleThe Journal of biological chemistry2025
RIPC improves myocardial injury by promoting mitochondrial protection via the PGC-1α/Nrf2 pathway.
Article in The Journal of biological chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases.Journal of translational medicine · 2026Review
- Circulating miRNAs Correlate With rIPC-Induced Cardioprotection and Its Impairment in Diabetic Myocardial Infarction via AMPK Signalling.Journal of cellular and molecular medicine · 2026Article
- Translational Barriers and Optimization Strategies for Remote Ischemic Conditioning to Enhance Stroke Cerebroprotection.Biomolecules · 2026Review
- PGC1α alleviates M1 macrophage polarization through dual regulation of succinate metabolism and TRAF5 expression to mitigate TLR4/NF-κB-driven inflammatory cascades and myocardial ischemia/reperfusion injury.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) is a common condition with high morbidity and mortality rates. Remote ischemic preconditioning (RIPC) activates the endogenous protective mechanisms by promoting ischemic tolerance and mitigating the subsequent damage caused by fatal ischemia. Maintaining mitochondrial function is imperative for the prevention of myocardial ischemia. The current study aims to evaluate the therapeutic effects of RIPC on MI with a focus on the mechanisms involved in mitochondrial function. In our study, patients with MI who underwent coronary angiography were randomly assigned to either the RIPC group (n = 20) or the control group (n = 20). RIPC intervention was administered preoperatively by inflating a blood pressure cuff on the upper arm to 200 mmHg for four cycles of 5 min each, interspersed with 5-min reperfusion intervals. The process alleviated myocardial injury among the participants, accompanied by a significant elevation in the serum concentrations of PGC-1α and Nrf2 levels in the serum. In vitro studies showed that RIPC can protect cardiomyocytes against ischemic injury by preserving the mitochondrial morphology, maintaining mitochondrial membrane integrity, and reducing oxidative stress. In vivo experimental findings illustrated that RIPC mitigated myocardial structural damage in mice by augmenting mitochondrial function, leading to significant cardiac protection, as evidenced by improved cardiac function and reduced infarct size. Moreover, the protective effects of RIPC were abolished upon silencing of PGC-1α. Collectively, the results indicated that RIPC activates the PGC-1α/Nrf2 signaling pathway to rescue cardiomyocytes by maintaining mitochondrial function during ischemic insult, suggesting a promising strategy for preventing cardiac ischemia injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.